<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04782960</url>
  </required_header>
  <id_info>
    <org_study_id>Subconjunctival bupivacaine</org_study_id>
    <nct_id>NCT04782960</nct_id>
  </id_info>
  <brief_title>Subconjunctival Bupivacaine in Strabismus Surgery</brief_title>
  <official_title>The Effect of Subconjunctival Bupivacaine Injection in Squint Surgery for Postoperative Analgesia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fayoum University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fayoum University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aimed to assess the effectiveness of the Subconjunctival bupivacaine on&#xD;
      postoperative pain in Strabismus surgery under general anaesthesia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      40 patients will schedule for elective Strabismus surgery under general anaesthesia and&#xD;
      randomly allocated into two groups to receive Subconjunctival 0.5%Bupivacaine group(B) or&#xD;
      Subconjunctival placebo 0.9% normal saline group at the end of the surgery and assess the&#xD;
      postoperative pain at 0th,30th, 60th,2nd h, 4h,6h,12h,24h.and post operative nausea and&#xD;
      vomiting.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2021</start_date>
  <completion_date type="Anticipated">May 2021</completion_date>
  <primary_completion_date type="Anticipated">May 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Visual analog scale (VAS) pain score</measure>
    <time_frame>5 minutes after extubation</time_frame>
    <description>Range, 0_10;0,no pain ;10,worst pain</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Nausea and vomiting</measure>
    <time_frame>24 hours postoperatively</time_frame>
    <description>Operation related side effect</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Patient satisfaction</measure>
    <time_frame>24 hours postoperatively</time_frame>
    <description>Will be evaluated according to satisfaction score (poor=0, fair=1, good=2, excellent=3)</description>
  </other_outcome>
  <other_outcome>
    <measure>Visual analog scale (VAS) pain score</measure>
    <time_frame>30 minutes after extubation</time_frame>
    <description>Range, 0_10;0,no pain ;10,worst pain</description>
  </other_outcome>
  <other_outcome>
    <measure>Visual analog scale (VAS) pain score</measure>
    <time_frame>60 minutes after extubation</time_frame>
    <description>Range, 0_10;0,no pain ;10,worst pain</description>
  </other_outcome>
  <other_outcome>
    <measure>Visual analog scale (VAS) pain score</measure>
    <time_frame>2 hours after extubation</time_frame>
    <description>Range, 0_10;0,no pain ;10,worst pain</description>
  </other_outcome>
  <other_outcome>
    <measure>Visual analog scale (VAS) pain score</measure>
    <time_frame>4 hours after extubation</time_frame>
    <description>Range, 0_10;0,no pain ;10,worst pain</description>
  </other_outcome>
  <other_outcome>
    <measure>Visual analog scale (VAS) pain score</measure>
    <time_frame>6 hours after extubation</time_frame>
    <description>Range, 0_10;0,no pain ;10,worst pain</description>
  </other_outcome>
  <other_outcome>
    <measure>Visual analog scale (VAS) pain score</measure>
    <time_frame>12 hours after extubation</time_frame>
    <description>Range, 0_10;0,no pain ;10,worst pain</description>
  </other_outcome>
  <other_outcome>
    <measure>Visual analog scale (VAS) pain score</measure>
    <time_frame>24 hours after extubation</time_frame>
    <description>Range, 0_10;0,no pain ;10,worst pain</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Anesthesia, Local</condition>
  <arm_group>
    <arm_group_label>20 patients receive Subconjunctival bupivacaine of the end of the surgery</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>20 patients receive Subconjunctival bupivacaine in the end of operation and monitoring postoperative pain score</description>
  </arm_group>
  <arm_group>
    <arm_group_label>20 patients receive Subconjunctival placebo in the end of operation</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>20 patients receive Subconjunctival placebo in the end of operation and monitoring postoperative pain score</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Iocal anaesthetic bupivacaine</intervention_name>
    <description>Local anaesthetic Subconjunctival bupivacaine</description>
    <arm_group_label>20 patients receive Subconjunctival bupivacaine of the end of the surgery</arm_group_label>
    <other_name>Group (p)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>0.9 saline</description>
    <arm_group_label>20 patients receive Subconjunctival placebo in the end of operation</arm_group_label>
    <other_name>Group (s)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All patients aged 14 _30 years old with body mass index 18_28kg/m.&#xD;
&#xD;
          -  American Anaesthesiologist Association physical states I,II.&#xD;
&#xD;
          -  singed informed consent to participate in the study and were scheduled for strabismus&#xD;
             operations under general anaesthesia.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  were patients with chronic pain.&#xD;
&#xD;
          -  ocular hypertension.&#xD;
&#xD;
          -  inability to communicate.&#xD;
&#xD;
          -  history of hematological disease.&#xD;
&#xD;
          -  allergy to local anesthetic drugs.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohammad A Hamed, MD</last_name>
    <role>Study Director</role>
    <affiliation>Fayoum University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Abeer Sh Goda</last_name>
    <phone>01005151706</phone>
    <email>Asg06@fayoum.edu.eg</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Amr H Mahmoud, Msc</last_name>
    <phone>01004349592</phone>
    <phone_ext>002</phone_ext>
    <email>Ah1240@fayoum.edu.eg</email>
  </overall_contact_backup>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>February 16, 2021</study_first_submitted>
  <study_first_submitted_qc>March 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 4, 2021</study_first_posted>
  <last_update_submitted>March 2, 2021</last_update_submitted>
  <last_update_submitted_qc>March 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fayoum University</investigator_affiliation>
    <investigator_full_name>abeer shaban</investigator_full_name>
    <investigator_title>Lecture of Anesthesiology</investigator_title>
  </responsible_party>
  <keyword>Subconjunctival bupivacaine.</keyword>
  <keyword>Strabismus surgery.</keyword>
  <keyword>Postoperative analgesia.</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Strabismus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
    <mesh_term>Anesthetics</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

